Secondary Logo

Journal Logo

Most Popular Articles

ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19

Möhlendick, Birte; Schönfelder, Kristina; Breuckmann, Katharina; More

Pharmacogenetics and Genomics. 31(8):165-171, October 2021.

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

van der Wouden, Cathelijne H.; Böhringer, Stefan; Cecchin, Erika; More

Pharmacogenetics and Genomics. 30(6):131-144, August 2020.

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population

Saksit, Niwat; Tassaneeyakul, Wichittra; Nakkam, Nontaya; More

Pharmacogenetics and Genomics. 27(7):255-263, July 2017.

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?

Kapoor, Ritika; Martinez-Vega, Rosario; Dong, Di; More

Pharmacogenetics and Genomics. 25(2):60-72, February 2015.

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Tassaneeyakul, Wichittra; Jantararoungtong, Thawinee; Chen, Pei; More

Pharmacogenetics and Genomics. 19(9):704-709, September 2009.

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

de Keyser, Catherine E.; Peters, Bas J.M.; Becker, Matthijs L.; More

Pharmacogenetics and Genomics. 24(1):43-51, January 2014.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics. 26(8):397-401, August 2016.

Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension

Thomeas-McEwing, Vasiliki; Psotka, Mitchell A.; Gamazon, Eric R.; More

Pharmacogenetics and Genomics. 32(4):144-151, June 2022.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

Lewis, Joshua P.; Horenstein, Richard B.; Ryan, Kathleen; More

Pharmacogenetics and Genomics. 23(1):1-8, January 2013.

Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia

Schuhmacher, Anna; Mössner, Rainald; Quednow, Boris B.; More

Pharmacogenetics and Genomics. 19(11):843-851, November 2009.

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

Suvichapanich, Supharat; Fukunaga, Koya; Zahroh, Hilyatuz; More

Pharmacogenetics and Genomics. 28(7):167-176, July 2018.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation

Nenonen, Hannah A.; Lindgren, Ida A.; Prahl, Alexandra S.; More

Pharmacogenetics and Genomics. 29(5):114-120, July 2019.

The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia

Oosterom, Natanja; Berrevoets, Marijn; den Hoed, Marissa A.H.; More

Pharmacogenetics and Genomics. 28(10):223-229, October 2018.

Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate

Stamp, Lisa K.; Chapman, Peter T.; O'Donnell, John L.; More

Pharmacogenetics and Genomics. 20(6):367-376, June 2010.

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

Hertz, Daniel L.; Douglas, Julie A.; Kidwell, Kelley M.; More

Pharmacogenetics and Genomics. 31(5):116-123, July 2021.

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

Selinski, Silvia; Blaszkewicz, Meinolf; Lehmann, Marie-Louise; More

Pharmacogenetics and Genomics. 21(10):673-678, October 2011.

4β-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians

Diczfalusy, Ulf; Miura, Jun; Roh, Hyung-Keun; More

Pharmacogenetics and Genomics. 18(3):201-208, March 2008.

Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care

Truong, Tien M.; Apfelbaum, Jeffrey L.; Schierer, Emily; More

Pharmacogenetics and Genomics. 32(3):79-86, April 2022.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics

Chan, Sze Ling; Samaranayake, Nilakshi; Ross, Colin J.D.; More

Pharmacogenetics and Genomics. 26(1):28-39, January 2016.

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria

St Jean, Pamela L.; Koh, Gavin C.K.W.; Breton, John J.; More

Pharmacogenetics and Genomics. 30(7):161-165, September 2020.

Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation

Ueshima, Satoshi; Hira, Daiki; Fujii, Ryo; More

Pharmacogenetics and Genomics. 27(9):329-336, September 2017.

Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation

Ali, Zainab Omer; Bader, Loulia; Mohammed, Shaaban; More

Pharmacogenetics and Genomics. 32(5):183-191, July 2022.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi; Wilkinson, Grant R.; Nutescu, Edith A.; More

Pharmacogenetics and Genomics. 16(2):101-110, February 2006.

Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to β2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease

Konno, Satoshi; Makita, Hironi; Hasegawa, Masaru; More

Pharmacogenetics and Genomics. 21(11):687-693, November 2011.

Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

Benito, Rocío; Lumbreras, Eva; Abáigar, María; More

Pharmacogenetics and Genomics. 22(5):381-388, May 2012.

Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon

Ferreira, Guilherme Motta Antunes; Ribeiro Elias, Anna Beatriz; Nascimento, Joabi; More

Pharmacogenetics and Genomics. 30(8):184-189, October 2020.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals

Lubomirov, Rubin; Arab-Alameddine, Mona; Rotger, Margalida; More

Pharmacogenetics and Genomics. 23(1):9-18, January 2013.

Show: